Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends



Rating:

Share or cite this content

Citations should be made in the following way:
P. Ireland (Newcastle Upon Tyne, United Kingdom), L. Langlands (Newcastle Upon Tyne, United Kingdom), C. Donaldson (Newcastle Upon Tyne, United Kingdom), A. Simpson (Newcastle Upon Tyne, United Kingdom), I. Forrest (Newcastle Upon Tyne, United Kingdom), S. Wiscombe (Newcastle Upon Tyne, United Kingdom), W. Funston (Newcastle Upon Tyne, United Kingdom). Pneumocystis jiroveci Pneumonia prophylaxis in patients treated with mycophenolate mofetil for interstitial lung disease. 2543

Member's Comments

No comment yet.

Related content which might interest you: Mycophenolate mofetil and azathioprine in chronic hypersensitivity pneumonitis Source: International Congress 2016 – Orphan diseases I Year: 2016 Outbreak of pneumocystis jiroveci pneumonia among renal transplant patients Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment Year: 2013 Role of pneumocystis jiroveci in interstitial lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 557s Year: 2004 Compared efficacies of lung delivery using two nebulizers in the prophylaxis against pneumocystis carinii pneumonia Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections Year: 2016 Prognosis of pneumocystis jirovecii pneumonia in non-HIV patients Source: Annual Congress 2013 –Manifestations, scores and prognosis of community-acquired pneumonia Year: 2013 Pneumocystis jirovecii pneumonia prophylaxis in non-HIV infected patients on immunosuppression; a regional cross-sectional study Source: Annual Congress 2013 –Lung infections: a clinical point of view Year: 2013 Safety and effectiveness of mycophenolate mofetil in interstitial lung diseases Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Pneumocystis pneumonia in the non-HIV population Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 Lymphopoenia and pneumocystis jiroveci (PCP) prophylaxis experience in non-specific interstitial pneumonitis (NSIP) Source: International Congress 2014 – ILDs 2 Year: 2014 Impact of mycophenolate mofetil on lung function in chronic hypersensitivity pneumonitis and connective tissue disease related-ILD Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 Pneumocystis carinii pneumonia in an otherwise healthy patient Source: Eur Respir J 2003; 22: Suppl. 45, 334s Year: 2003 Hospital-acquired pneumonia in patients receiving immunosuppressive therapy Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 Cryptogenic organizing pneumonia – Results of treatment with clarithromycin versus corticosteroids Source: International Congress 2016 – Orphan diseases II Year: 2016 Pulmonary alveolar proteinosis due to mycophenolate and cyclosporine combination therapy in a renal transplant recipient Source: Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach Year: 2012 Experience of azathioprine therapy for idiopathic interstitial pneumonia in young infants in Japan Source: Eur Respir J 2006; 28: Suppl. 50, 118s Year: 2006 Cyclosporin A is effective for the patients with interstitial pneumonia resistant to steroid therapy Source: Eur Respir J 2004; 24: Suppl. 48, 507s Year: 2004 Cyclosporine A in the treatment of idiopathic pulmonary fibrosis/usual interstitial pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 62s Year: 2002 Pneumocystis carinii (jiroveci) pneumonia (PCP) in ICU patients with hematological malignancies Source: Eur Respir J 2004; 24: Suppl. 48, 548s Year: 2004 Assessement of pulmonary TB in association with pneumocystis jiroveci Source: Annual Congress 2008 - Difficult tuberculosis cases Year: 2008 Use of mycophenolate mofetil for the treatment of hypersensitivity pneumonitis> Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020